"Spot" NK cell therapy for the first acute myeloid leukemia patients to administer, Dr. Carl June is optimistic about the development of NK cells in the field of tumor immunity, the development of the medical mammoth.

Nearly 100 authoritative leaders of domestic bio innovative drugs have spoken, hundreds of leading Biopharmaceutical Enterprises have paid close attention to it. More than 1000 pharmaceutical peers have signed up to participate. Dozens of innovative drug technologies have been collectively unveiled. Four hot biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine, and gene therapy, are focused on. 2020 bpit The biopharmaceutical innovation technology conference will be held in Nanjing International Youth Cultural Center. From July 19 to 21, 2020, we will pay tribute to the next golden decade of innovative drugs and witness the new goals and new mileage of Chinese innovative drugs! This article is originally created by emameck, welcome to share, and reprint must be authorized. June 30, 2020 / emedclub news / - - recently, the clinical biopharmaceutical company kiadis Pharma announced that the first relapsed / refractory acute myeloid leukemia (R / R AML) patient was successfully administered k-nk cells at the James Cancer Hospital (osucc James), Ohio State University Comprehensive Cancer Center.the k-nk cell therapy is a "off the shelf" NK cell therapy produced at osucc James cell therapy laboratory based on kiadis's proprietary fc21 and universal donor platform.it is expected to provide valuable data for the development plan of k-nk003, a candidate product of kiadis.trial design the phase I clinical study (nct04220684) will evaluate k-nk cells in 56 patients with primary refractory AML and myelodysplastic syndrome (MDS). Subjects will receive six doses of NK cells ranging from 1x107 cells / kg to 1x108 cells / kg after receiving attenuated chemotherapy.the primary objective of this study was to evaluate the safety of k-nk cells, and the secondary objective was to evaluate the remission rate and optimal dose.the experimental results are expected to provide further clinical concept validation for k-nk003 product of kiadis.sumithira vasu, medical director of the cell therapy laboratory at osucc James and lead investigator of the clinical trial, said: "this universal donor derived NK cell therapy is an exciting new experimental treatment option for R / R AML and MDS patients, which can inject a large number of functional NK cells immediately when needed.at present, this therapy has completed the first patient administration, which is an important step in our clinical research."Andrew Sandler, chief medical officer of kiadis, commented:" the experiment used a new, "off the shelf" NK cell product to treat a group of patients who were seriously ill and difficult to treat.we are very excited about this experiment, and it is a step forward for us to extend k-nk cell therapy to a wider range of cancer species."kiadis Pharma, founded in 1997, is striving to become a fully integrated biopharmaceutical company dedicated to developing innovative therapies for life-threatening diseases.kiadis was listed on the pan European stock exchange Amsterdam exchange and Brussels Stock Exchange on July 2, 2015 with the stock code of KDS.in April 2019, kiadis successfully acquired cytosen therapeutics.recommended reading: combining T cells with NK cells and supported by Dr. Carl June, a pioneer of car-t, the company is worth looking forward to. The company, headquartered in Amsterdam, the Netherlands, and has offices all over the United States, aims to use the natural forces of human beings and the collective immune system to provide the best cells to reconstruct medicine.at present, the company's key R & D project is NK cell therapy.} the R & D pipeline of kiadis (photo source: kiadis) based on the company's unique unique universal donor platform, NK cells derived from the source, and Pm21 particle in vitro proliferation and activation technology, kiadis has developed a number of "spot" or / and haploid NK cell projects covering hematoma and solid tumors, so as to provide them to a wide range of audiences more quickly and economically.k-nk002: it is the candidate product of NK cells with the fastest progress in kiadis. Phase II clinical trials are being conducted to evaluate the role of NK cells from haploidentical donors in preventing relapse after AML and MDS transplantation. the study was designed based on positive preclinical data from MD Anderson Cancer Center: complete remission rate (CR) was 69%, and historical CR was 20% - 26%. k-nk003: phase I / II clinical trials are under way to evaluate NK cells as a treatment for R / R AML. k-nk00x: at present, preclinical studies on hematoma and solid tumor are being carried out as a treatment method. in fact, the pioneer of car-t therapy, Dr. Carl June of the University of Pennsylvania, is also a member of the scientific advisory board of kiadis. Professor Carl h. June of the University of Pennsylvania commented: "NK cell therapy may significantly advance the field of tumor immunology. moreover, I believe that there is a great synergy in the field of NK cells and T cells, and this combination may help patients with severe diseases. I am very happy to join the Scientific Advisory Committee of kiadis. "NK cell therapy is well known that NK cells play an important role in the body's innate immune system. As early as the 1970s, researchers described them, but it was only in the last 15 years that people gradually understood the complexity and therapeutic potential of NK cells in helping fight cancer and other diseases. at present, NK cell therapy has become a hot field. natural killer cells (NK cells) are a part of the innate immune system of the human body. They can quickly respond to various pathogens encountered in the body. They are the first line of defense against dangerous infection or abnormal cells and the normal reserve of the body against cancer. different from other immune cells (T cells and B cells), T cells usually need to detect MHC on the surface of target cells to release cytokines and then cause target cell lysis or apoptosis; NK cells can recognize these cells and conduct rapid immune response without antibodies or MHC. because NK cells are different from T cells in non-specific target recognition and killing mechanism, it has attracted the attention of many researchers and investors. } NK cells (image source: NIAID) on October 1, 2018, dragonfly therapeutics announced that it had entered into a US $695 million license agreement with Merck, which will enable Merck to use trinket Gamma Platform development of a series of solid tumor project exclusive rights. neither the number of items nor the type of solid tumor were disclosed. on December 13, 2018, celgene obtained two kinds of trinkets from Dragonfly therapeutics with a total of $24 million in advance, future milestones and royalties Gamma Licensing of immunotherapy candidate drugs. in September 2019, nkarta therapeutics received a US $114 million round B financing led by samsara bioccapital to support its clinical development plan of "spot" NK cell products. nkx101, the main candidate product of nkarta, is an allogeneic NK cell targeting NKG2D and is currently in clinical trials in hematoma and solid tumors. recommended reading: the battle for NK cell therapy is about to start. Nkarta has invested $114 million to promote the clinical application of its car-nk project; Johnson's Janssen biotechnology company has reached a US $3.1 billion cooperation agreement to create new car-nk and car-t cell candidates using fat's IPSC product platform and Janssen's proprietary tumor antigen binders. recommended reading: IPSC derived car-nk / T cell therapy has reached a global cooperation of US $3.1 billion. In addition, many other large pharmaceutical companies have set up the field of NK cells, such as Takeda, abbvie, BMS / celgene, etc. focusing on four popular biomedical fields, such as tumor immunity, new antibodies, stem cell regenerative medicine and gene therapy, the 2020 bpit biopharmaceutical innovation technology conference will be held in Nanjing International Youth Culture Center, China, on July 19-21, 2020! Click the picture above to view the agenda of the conference